News Release Dated May 14, 2024
Company: Japan System Techniques Co., Ltd.
Representative: Takeaki Hirabayashi, President and CEO
Stock code: 4323, Tokyo Stock Exchange, Prime Market
Contact: Taku Hirabayashi, Director and Senior Officer
Tel: +81-6-4560-1000

Start of COPD Patient Education Joint Programwith the City of Takamatsu and AstraZeneca K.K.
Japan System Techniques Co., Ltd. (JAST) has established an agreement with the City of Takamatsu andAstraZeneca K.K. for cooperation concerning education programs for individuals who have chronic
obstructive pulmonary disease (COPD). The details are as per attached.
This matter will have only a negligible effect on JAST’s results of operations. An announcement will be madepromptly if there is any additional information that should be disclosed.

Launch the Future

NEWS RELEASE

May 14, 2024
Japan System Techniques Co., Ltd.

Start of COPD Patient Education Joint Programwith the City of Takamatsu and AstraZeneca K.K.
Japan System Techniques Co., Ltd. (JAST) has established an agreement with the City of Takamatsu and AstraZeneca K.K.
for cooperation concerning education programs for individuals who have chronic obstructive pulmonary disease (COPD).
■ Background of the Joint COPD Education Program
COPD is a group of lung diseases including emphysema, chronic bronchitis and others that over time makes breathing
increasingly difficult. The primary causes are smoking over many years and problems involving the growth of the lungs. In
recent years, there has been increasing interest concerning the link between COPD and frailty and sarcopenia. Inflammation
throughout the body can cause a variety of other disorders of the organs in addition to COPD (source: SMART LIFE PROJECT“COPD”, Ministry of Health, Labour and Welfare, https://www.smartlife.mhlw.go.jp/event/disease/copd/, viewed on April 23,2024)
The City of Takamatsu wanted to start programs for the diagnosis and proper treatment of COPD as part of measures to help
residents enjoy a long healthy life. The goal is to prevent this disease from becoming serious. To accomplish this, Takamatsu
city officials began to examine ways to work with companies for educational programs for advances regarding awareness ofCOPD and the diagnosis and treatment of this chronic disease. This process led to the decision to work with AstraZeneca
K.K., which has activities for increasing the proper treatment of COPD in accordance with guidelines. The goals arepreventing COPD symptoms from worsening and building sound three-way relationships encompassing AstraZeneca K.K.,
patients and healthcare professionals. To accomplish these goals, this company considered an alliance with JAST. The reason
is JAST’s use of data analysis involving national health insurance and health care for people in the later stages of old age forthe purpose of providing local governments and the national government with ideas for ways to alter the behavior of people.
The goals are improvements in the health and quality of life of residents of Japan.
AstraZeneca K.K. and JAST support the following objectives of the planned COPD educational activities of the City ofTakamatsu and recognize the medical significance of the city’s plan. As a result, the two companies responded to the requestof Takamatsu city officials to establish an alliance based on the terms of the contract signed. The COPD educational activities
have the following two objectives.
(1) Contribute to an increase in suitable COPD treatments and knowledge about these treatments.
(2) For improving the health and quality of life of the people of Japan, increase activities for altering the behavior of people
based on the analysis of national health insurance data and data about health care for people in the later stages of old age■ Upcoming Activities
JAST wants this partnership to become a new approach for national health insurance and health care for people in the laterstages of old age. Activities are expected to result in advances involving the awareness, diagnosis and treatment of COPD.
JAST will continue to use educational activities involving diseases and disorders to help people covered by health insurance
to remain in good health.
■ Inquiries
Japan System Techniques Co., Ltd.
Contact: Healthcare Innovation Business Division
TEL: +81-3-6718-2785 (Tokyo), +81-6-4560-1050 (Osaka)E-mail: jmics-sales@jast.co.jp
URL: https://jmics.jp/1